Hybritech got FDA approval for a cancer test.

The product, Tandem-E AFP, is used to measure the level of alpha fetal protein in blood taken from men with testicular cancer. The discovery that testicular cancer cells produce AFP has pushed the cure rate from 60% a decade ago to more than 90% today. Officials of San Diego-based Hybritech hope to eventually capture about 25% of the AFP test market, estimated at about $1.7 million in the United States and at nearly $6 million in other parts of the world, primarily in Japan.